Bayer (FRA:BAYN) has been given a €129.00 ($153.57) target price by Sanford C. Bernstein in a note issued to investors on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price objective indicates a potential upside of 24.04% from the stock’s previous close.
BAYN has been the subject of a number of other research reports. S&P Global set a €126.00 ($150.00) target price on Bayer and gave the stock a “buy” rating in a report on Thursday, October 26th. DZ Bank reiterated a “buy” rating on shares of Bayer in a report on Monday, December 11th. equinet set a €118.00 ($140.48) target price on Bayer and gave the stock a “buy” rating in a report on Friday, October 13th. BNP Paribas set a €130.00 ($154.76) target price on Bayer and gave the stock a “buy” rating in a report on Monday, September 25th. Finally, UBS Group set a €125.00 ($148.81) target price on Bayer and gave the stock a “buy” rating in a report on Monday, November 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of €121.67 ($144.84).
Shares of Bayer (BAYN) opened at €104.00 ($123.81) on Wednesday. Bayer has a 12 month low of €99.69 ($118.68) and a 12 month high of €123.82 ($147.40). The stock has a market capitalization of $86,180.00 and a P/E ratio of 27.88.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.